aTyr Pharma Inc. (NASDAQ: ATYR) announced that its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis did not meet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE